Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen … & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … of sepofarsen. This marks an important milestone for ProQR, as well as for the LCA10 and broader inherited retinal …
… ProQR to Present Findings from Phase 1/2 Interim Analysis of … & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … page on the Investors section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Receives Orphan Drug Designation from FDA for QR-1123 … Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or adRP,” said Daniel de Boer, Chief Executive Officer of ProQR. “It highlights the unmet need for patients with this …